Imaging in staging of malignant lymphoma: a systematic review

Jemal, 2007, Cancer statistics, 2007., CA Cancer J Clin, 57, 43, 10.3322/canjclin.57.1.43 Armitage, 2005, Staging non-Hodgkin lymphoma., CA Cancer J Clin, 55, 368, 10.3322/canjclin.55.6.368 Connors, 2005, State-of-the-art therapeutics: Hodgkin's lymphoma., J Clin Oncol, 23, 6400, 10.1200/JCO.2005.05.016 Lister, 1989, Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting., J Clin Oncol, 7, 1630, 10.1200/JCO.1989.7.11.1630 Jhanwar, 2006, The role of PET in lymphoma., J Nucl Med, 47, 1326 Rohren, 2004, Clinical applications of PET in oncology., Radiology, 231, 305, 10.1148/radiol.2312021185 Blodgett, 2007, PET/CT: form and function., Radiology, 242, 360, 10.1148/radiol.2422051113 Von Schulthess, 2006, Integrated PET/CT: current applications and future directions., Radiology, 238, 405, 10.1148/radiol.2382041977 Lauenstein, 2006, Emerging techniques: whole-body screening and staging with MRI., J Magn Reson Imaging, 24, 489, 10.1002/jmri.20666 Ladd, 2006, Whole-body MR diagnostic concepts., Rofo, 178, 763, 10.1055/s-2006-926914 Rosenberg, 1971, Report of the Committee on Hodgkin's Disease Staging Procedures., Cancer Res, 31, 1862 Kreel, 1976, The EMI whole body scanner in the demonstration of lymph node enlargement., Clin Radiol, 27, 421, 10.1016/S0009-9260(76)80102-X Prokop, 2003, Multislice CT: technical principles and future trends., Eur Radiol, 13, S3, 10.1007/s00330-003-2178-z Rydberg, 2000, Multisection CT: scanning techniques and clinical applications., Radiographics, 20, 1787, 10.1148/radiographics.20.6.g00nv071787 Lucey, 2005, Mesenteric lymph nodes: detection and significance on MDCT., AJR Am J Roentgenol, 184, 41, 10.2214/ajr.184.1.01840041 Vinnicombe, 2003, Computerised tomography in the staging of Hodgkin's disease and non-Hodgkin's lymphoma., Eur J Nucl Med Mol Imaging, 30, S42, 10.1007/s00259-003-1159-4 Phelps, 1975, Application of annihilation coincidence detection to transaxial reconstruction tomography., J Nucl Med, 16, 210 Paul, 1987, Comparison of fluorine-18–2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma., J Nucl Med, 28, 288 Moog, 1997, Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging., Radiology, 203, 795, 10.1148/radiology.203.3.9169707 De Wit, 1997, Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma., Ann Oncol, 8, S57, 10.1093/annonc/8.suppl_1.S57 Bangerter, 1996, New diagnostic imaging procedures in Hodgkin's disease., Ann Oncol, 7, S55, 10.1093/annonc/7.suppl_4.S55 Barrington, 1995, Staging of Burkitt's lymphoma and response to treatment monitored by PET scanning., Clin Oncol (R Coll Radiol), 7, 334, 10.1016/S0936-6555(05)80549-7 Zhang, 2002, Oncological diagnosis using positron coincidence gamma camera with fluorodeoxyglucose in comparison with dedicated PET., Br J Radiol, 75, 409, 10.1259/bjr.75.893.750409 Tatsumi, 2001, Whole-body hybrid PET with 18F-FDG in the staging of non-Hodgkin's lymphoma., J Nucl Med, 42, 601 Boren, 1999, Comparison of FDG PET and positron coincidence detection imaging using a dual-head gamma camera with 5/8-inch NaI(Tl) crystals in patients with suspected body malignancies., Eur J Nucl Med, 26, 379, 10.1007/s002590050401 Shreve, 1998, Oncologic diagnosis with 2-[fluorine-18]fluoro-2-deoxy-D-glucose imaging: dual-head coincidence gamma camera versus positron emission tomographic scanner., Radiology, 207, 431, 10.1148/radiology.207.2.9577492 Wahl, 1999, To AC or not to AC: that is the question., J Nucl Med, 40, 2025 Kelloff, 2007, FDG-PET Lymphoma Demonstration Project Invitational Workshop., Acad Radiol, 14, 330, 10.1016/j.acra.2006.12.003 Coleman, 2006, Early 18F-labeled fluoro-2-deoxy-D-glucose positron emission tomography scanning in the lymphomas: changing the paradigms of treatments?, Cancer, 107, 1425, 10.1002/cncr.22178 Gallamini, 2007, Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study., J Clin Oncol, 25, 3746, 10.1200/JCO.2007.11.6525 Damadian, 1980, Field focusing n.m.r. (FONAR) and the formation of chemical images in man., Philos Trans R Soc Lond B Biol Sci, 289, 489, 10.1098/rstb.1980.0067 Lauterbur, 1980, Progress in n.m.r. zeugmatography imaging., Philos Trans R Soc Lond B Biol Sci, 289, 483, 10.1098/rstb.1980.0066 Schmidt, 2007, High-resolution whole-body magnetic resonance imaging applications at 1.5 and 3 Tesla: a comparative study., Invest Radiol, 42, 449, 10.1097/01.rli.0000262089.55618.18 Schick, 2005, Whole-body MRI at high field: technical limits and clinical potential., Eur Radiol, 15, 946, 10.1007/s00330-005-2678-0 Kelly, 1997, The identification of bias in studies of the diagnostic performance of imaging modalities., Br J Radiol, 70, 1028, 10.1259/bjr.70.838.9404207 Whiting, 2003, The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews., BMC Med Res Methodol, 3, 25, 10.1186/1471-2288-3-25 Whiting, 2006, Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies., BMC Med Res Methodol, 6, 9, 10.1186/1471-2288-6-9 Rigacci, 2005, 18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: long-term results., Oncol Rep, 14, 1209 La Fougere, 2006, Value of PET/CT versus PET and CT performed as separate investigations in patients with Hodgkin's disease and non-Hodgkin's lymphoma., Eur J Nucl Med Mol Imaging, 33, 1417, 10.1007/s00259-006-0171-x Hernandez-Pampaloni, 2006, F-18 FDG-PET imaging and correlation with CT in staging and follow-up of pediatric lymphomas., Pediatr Radiol, 36, 524, 10.1007/s00247-006-0152-z Meany, 2007, Utility of PET scans to predict disease relapse in pediatric patients with Hodgkin lymphoma., Pediatr Blood Cancer, 48, 399, 10.1002/pbc.20797 Bjurberg, 2006, FDG-PET in the detection of residual disease and relapse in patients with Hodgkin's lymphoma: Experience from a Swedish centre., Acta Oncol, 45, 743, 10.1080/02841860600644724 Zinzani, 2006, Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients., Ann Oncol, 17, 1296, 10.1093/annonc/mdl122 Filmont, 2004, Conventional imaging and 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography for predicting the clinical outcome of patients with previously treated Hodgkin's disease., Mol Imaging Biol, 6, 47, 10.1016/S1536-1632(03)00107-0 Dittmann, 2001, Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma., Oncol Rep, 8, 1393 Filmont, 2003, Conventional imaging and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography for predicting the clinical outcome of previously treated non-Hodgkin's lymphoma patients., Mol Imaging Biol, 5, 232, 10.1016/S1536-1632(03)00086-6 Mikhaeel, 2000, 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT., Leuk Lymphoma, 39, 543, 10.3109/10428190009113384 Reinhardt, 2005, Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?, Ann Oncol, 16, 1524, 10.1093/annonc/mdi271 Freudenberg, 2004, FDG-PET/CT in re-staging of patients with lymphoma., Eur J Nucl Med Mol Imaging, 31, 325, 10.1007/s00259-003-1375-y Mikosch, 2003, Accuracy of whole-body 18F-FDP-PET for restaging malignant lymphoma., Acta Med Austriaca, 30, 41, 10.1046/j.1563-2571.2003.03003.x Mikhaeel, 2000, 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas., Ann Oncol, 11, S147, 10.1093/annonc/11.suppl_1.S147 Bangerter, 1999, Role of whole body FDG-PET imaging in predicting relapse of malignant lymphoma in patients with residual masses after treatment., Radiography, 5, 155, 10.1016/S1078-8174(99)90024-X Bangerter, 1999, Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest., Acta Oncol, 38, 799, 10.1080/028418699432969 Stumpe, 1998, Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography., Eur J Nucl Med, 25, 721, 10.1007/s002590050275 Schaefer, 2007, Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy—is biopsy of FDG-avid lesions still needed?, Radiology, 244, 257, 10.1148/radiol.2441060810 Rhodes, 2006, Utility of FDG-PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma., J Pediatr Hematol Oncol, 28, 300, 10.1097/01.mph.0000212912.37512.b1 Semelka, 2007, Imaging strategies to reduce the risk of radiation in CT studies, including selective substitution with MRI., J Magn Reson Imaging, 25, 900, 10.1002/jmri.20895 Barentsz, 2006, Commonly used imaging techniques for diagnosis and staging., J Clin Oncol, 24, 3234, 10.1200/JCO.2006.06.5946 Executive Summary Board on Radiation Effects Research—Division on Earth and Life Studies editor Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII—Phase 2., 2005 Ansell, 2005, Non-Hodgkin lymphoma: diagnosis and treatment., Mayo Clin Proc, 80, 1087, 10.4065/80.8.1087 Hennessy, 2004, Non-Hodgkin lymphoma: an update., Lancet Oncol, 5, 341, 10.1016/S1470-2045(04)01490-1 Namasivayam, 2006, Adverse reactions to intravenous iodinated contrast media: a primer for radiologists., Emerg Radiol, 12, 210, 10.1007/s10140-006-0488-6 Pakos, 2005, 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis., J Nucl Med, 46, 958 Tsukamoto, 2007, The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification., Cancer, 110, 652, 10.1002/cncr.22807 Elstrom, 2003, Utility of FDG-PET scanning in lymphoma by WHO classification., Blood, 101, 3875, 10.1182/blood-2002-09-2778 Hoffmann, 2006, 18F-Fluoro-deoxy-glucose positron emission tomography in lymphoma of mucosa-associated lymphoid tissue: histology makes the difference., Ann Oncol, 17, 1761, 10.1093/annonc/mdl295 Alinari, 2006, 18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma., Leuk Lymphoma, 47, 2096, 10.1080/10428190600733499 Karam, 2006, Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas., Cancer, 107, 175, 10.1002/cncr.21967 Beal, 2005, FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases., Ann Oncol, 16, 473, 10.1093/annonc/mdi093 Hoffmann, 2003, 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma., Oncology, 64, 336, 10.1159/000070290 Hoffmann, 1999, Positron emission tomography with fluorine-18–2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type., Ann Oncol, 10, 1185, 10.1023/A:1008312726163 Najjar, 2001, Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL)., Cancer Biother Radiopharm, 16, 297, 10.1089/108497801753131372 Jerusalem, 2001, Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL)., Ann Oncol, 12, 825, 10.1023/A:1011169332265 Hoffmann, 2004, 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) does not visualize follicular lymphoma of the duodenum., Ann Hematol, 83, 276, 10.1007/s00277-003-0827-6 Valencak, 2004, Positron emission tomography with [18F] 2-fluoro-D-2- deoxyglucose in primary cutaneous T-cell lymphomas., Haematologica, 89, 115 Juweid, 2007, Use of positron emission tomography for response assessment of lymphoma: consensus recommendations of the Imaging Subcommittee of the International Harmonization Project in Lymphoma., J Clin Oncol, 25, 571, 10.1200/JCO.2006.08.2305 Perry, 2007, Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma., Eur J Haematol, 79, 205, 10.1111/j.1600-0609.2007.00895.x Castellucci, 2005, Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation., Nucl Med Commun, 26, 689, 10.1097/01.mnm.0000171781.11027.bb Castellucci, 2005, 18F-FDG PET in malignant lymphoma: significance of positive findings., Eur J Nucl Med Mol Imaging, 32, 749, 10.1007/s00259-004-1748-x Barrington, 2003, Limitations of PET for imaging lymphoma., Eur J Nucl Med Mol Imaging, 30, S117, 10.1007/s00259-003-1169-2 Brix, 2005, Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations., J Nucl Med, 46, 608 Brennan, 2005, A comparison of whole-body MRI and CT for the staging of lymphoma., AJR Am J Roentgenol, 185, 711, 10.2214/ajr.185.3.01850711 Kellenberger, 2004, Initial experience with FSE STIR whole-body MR imaging for staging lymphoma in children., Eur Radiol, 14, 1829, 10.1007/s00330-004-2432-z Schmidt, 2007, Whole-body imaging of the musculoskeletal system: the value of MR imaging., Skeletal Radiol, 36, 1109, 10.1007/s00256-007-0323-5 Runge, 2001, Safety of magnetic resonance contrast media., Top Magn Reson Imaging, 12, 309, 10.1097/00002142-200108000-00007 Murtz, 2007, Diffusion-weighted whole-body MR imaging with background body signal suppression: a feasibility study at 3.0 Tesla., Eur Radiol, 17, 3031, 10.1007/s00330-007-0717-8 Koh, 2007, Diffusion-weighted MRI in the body: applications and challenges in oncology., AJR Am J Roentgenol, 188, 1622, 10.2214/AJR.06.1403 Takahara, 2004, Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display., Radiat Med, 22, 275 Will, 2006, Diagnostic precision of nanoparticle-enhanced MRI for lymph-node metastases: a meta-analysis., Lancet Oncol, 7, 52, 10.1016/S1470-2045(05)70537-4 Klose, 2000, Primary staging of lymphomas: cost-effectiveness of FDG-PET versus computed tomography., Eur J Nucl Med, 27, 1457, 10.1007/s002590000323